Danish pharmaceutical firm Novo Nordisk's top executives have begun a high-level visit in China in June. As more multinational firms double down on their investments in China's healthcare and innovation ecosystem, Novo Nordisk's journey reveals the huge opportunities within the country's "Healthy China" development blueprint. 

CGTN's Xu Yi reports to unpack all key takeaways.